Meeting
2016 ASCO Annual Meeting
Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.
Authors
Sara Michele Federico
St. Jude Children's Research Hospital, Memphis, TN
Sara Michele Federico , Mary B McCarville , Clinton F. Stewart , Shenghua Mao , Jianrong Wu , Andrew M. Davidoff , Wayne Lee Furman , Victor M. Santana , Alberto S. Pappo , Fariba Navid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00665990
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10519)
DOI
10.1200/JCO.2016.34.15_suppl.10519
Abstract #
10519
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase 1b, open label, single institution trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
First Author: Ankit Madan
Poster
2016 ASCO Annual Meeting
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.
First Author: Birgit Geoerger
Poster
2015 ASCO Annual Meeting
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
First Author: Su Jin Lee
Poster
2014 ASCO Annual Meeting
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
First Author: Meredith K. Chuk